pharmaglobenews, Author at Pharma Globenewswire

EGFR Inhibitor Market Expected to Gain Momentum Through 2034 | DelveInsight

DelveInsight’s “EGFR Inhibitor Market Insights, Epidemiology, and Market Forecast-2034” report provides an in-depth analysis of the EGFR Inhibitor market, including historical and projected epidemiology trends, as well as market dynamics across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom,

19 November 2025

Market Insights

Myelofibrosis Market Poised to Expand Significantly at 9% CAGR from 2025 to 2034 | DelveInsight

The introduction of novel therapies, including BESREMi (PharmaEssentia/AOP Orphan Pharmaceuticals), INCB057643 (Incyte), XPOVIO (Karyopharm Therapeutics), RYTELO (Geron), REBLOZYL (Bristol Myers Squibb), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), among others, is poised to reshape the myelofibrosis treatment landscape. DelveInsight’s Myelofibrosis Market Insights report includes

19 November 2025

Market Insights

KRAS Inhibitors Market Set for Breakneck 35% CAGR Growth by 2034 | DelveInsight

The KRAS inhibitors market is projected to witness strong expansion, fueled by the growing burden of cancer, wider access to advanced therapies, and a promising pipeline featuring candidates such as Olomorasib (Eli Lilly), MK-1084 (Merck/Taiho/Astex Pharmaceuticals), Divarasib (Roche), Daraxonrasib (Revolution Medicines), Onvansertib

19 November 2025

Market Insights

Niemann-Pick Type C Market Poised for Strong 14.8% CAGR Growth (2025–2034) | DelveInsight

The NPC market remains constrained by the scarcity of approved therapies and a substantial unmet medical need. Nonetheless, upcoming treatments, including Cyclo Therapeutics’ Trappsol Cyclo, Azafaros’ oral small-molecule nizubaglustat (AZ-3102), and the early-stage candidate Adrabetadex (VTS-270), combined with increasing disease awareness, are

19 November 2025

News

NCFB Market on the Brink of Change as First DPP1 Inhibitor Marks Approval | DelveInsight

The NCFB market is entering a new phase as Insmed’s BRINSUPRI has achieved a major regulatory breakthrough, securing FDA approval as the first therapy and the first-ever DPP1 inhibitor. DelveInsight’s Non-cystic Fibrosis Bronchiectasis Market Report 2034 includes a comprehensive understanding of current

19 November 2025

Market Insights

Triple-Negative Breast Cancer Market to Showcase Growth at 4.7% CAGR Through 2034 | DelveInsight

The TNBC market is projected to expand, driven by rising disease prevalence, advances in targeted treatment options, and the introduction of new therapies, including DATROWAY [(Datopotamab Deruxtecan), AstraZeneca and Daiichi Sankyo], IMFINZI [(Durvalumab), AstraZeneca], PADCEV [(Enfortumab vedotin), Astellas Pharma and Pfizer], Tilarginine

19 November 2025

Uncategorised

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market was approximately USD 3 billion in 2024, Estimates DelveInsight

DelveInsight’s analysis reveals a rising burden of Interstitial Lung Disease (ILD) across major markets, with over 1 million diagnosed prevalent cases reported in the 7MM in 2024 and numbers projected to grow by 2034. In the US, more than 80,000 cases of

18 November 2025

pharmaglobenews

EGFR Inhibitor Market Expected to Gain Momentum Through 2034 | DelveInsight

Myelofibrosis Market Poised to Expand Significantly at 9% CAGR from 2025 to 2034 | DelveInsight

KRAS Inhibitors Market Set for Breakneck 35% CAGR Growth by 2034 | DelveInsight

Niemann-Pick Type C Market Poised for Strong 14.8% CAGR Growth (2025–2034) | DelveInsight

NCFB Market on the Brink of Change as First DPP1 Inhibitor Marks Approval | DelveInsight

Triple-Negative Breast Cancer Market to Showcase Growth at 4.7% CAGR Through 2034 | DelveInsight

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market was approximately USD 3 billion in 2024, Estimates DelveInsight

Recent Posts

Banner

Newsletter

Authors